Biowall Project

Helping you keep up with science

CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Clinical lymphoma, myeloma & leukemia

D Swan, R Henderson, C McEllistrim, …, J Krawczyk, P Murphy, M O’Dwyer

kedalionlabs.com

Leave a Reply Cancel reply

You must be logged in to post a comment.

Powered by WordPress | WP Newspaper by WP Mag Plus | Data sources